Oligonucleotide CRDMO Platform: Discovery to Commercial Manufacturing

The Integrated CRDMO Approach to Oligonucleotide Therapeutics: From Discovery to Commercial Manufacturing

The rapid expansion of oligonucleotide-based therapeutics has reshaped the drug development landscape over the past decade. These short, synthetic nucleic acid sequences, including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and messenger RNA (mRNA) constructs, offer the potential to target diseases at the genetic level. However, their journey from laboratory bench to commercial pharmacy is fraught with chemical, analytical, and regulatory complexities. One model that has gained traction to address these challenges is the fully integrated Contract Research, Development, and Manufacturing Organization (CRDMO) platform. According to WuXi TIDES, their oligonucleotide platform provides comprehensive services spanning drug discovery through commercial manufacturing for both drug substance and drug product. This approach aims to streamline the traditionally fragmented process of bringing a nucleic acid therapy to market.

Discovery Synthesis: Building the Oligonucleotide Toolkit

The earliest phase of oligonucleotide development demands speed and chemical flexibility. WuXi TIDES outlines discovery synthesis services that support high throughput library synthesis and custom synthesis at scales ranging from nanomoles to millimoles. Such capabilities are essential for screening thousands of candidate sequences to identify those with the optimal affinity, specificity, and stability. Their platform covers all major types of oligonucleotides, including their monomers, linkers, ligands, and conjugates. This includes DNA, ASOs, phosphorodiamidate morpholino oligomers (PMOs), microRNA (miRNA), siRNA, single guide RNA (sgRNA), and degenerate oligonucleotide pools. Additionally, the company offers dedicated analytical support for all required testing at this stage, ensuring that early candidates are thoroughly characterized before moving forward.

Beyond the standard linear nucleic acids, the platform also handles more complex constructs. For instance, oligonucleotide-peptide conjugates, oligonucleotide-drug conjugates, oligonucleotide-lipid conjugates, and oligonucleotide-GalNAc conjugates are all within scope. Dye-labelled oligonucleotides are also available for imaging and diagnostic applications. This breadth of chemistry is critical because many modern oligonucleotide therapeutics rely on conjugate moieties to improve cellular uptake, target specificity, or pharmacokinetics.

Scaling Up: From Millimoles to Commercial Batches

One of the greatest hurdles in oligonucleotide development is the seamless transition from small-scale discovery synthesis to the large-scale manufacturing required for preclinical, clinical, and ultimately commercial supply. WuXi TIDES states that they can scale up to any scale expressed in millimoles to moles, with ample capacity and proven commercial success. This scalability is underpinned by readily available research and development and manufacturing capacity, which they highlight as a key differentiator.

The scaling process introduces significant challenges. Oligonucleotide synthesis traditionally relies on solid-phase phosphoramidite chemistry, which is efficient at small scales but requires careful optimization for larger batches. Issues such as coupling efficiency, impurity profiles, and solvent usage become magnified. The platform's approach to conjugation chemistry is supported by what WuXi TIDES describes as seamless collaboration among oligonucleotide, peptide, and small molecule teams. This interdisciplinary integration is vital when a therapeutic demands multiple functional components, such as a GalNAc ligand conjugated to an siRNA to direct it to the liver.

New Technologies and Global Quality Standards

To address the limitations of traditional chemical synthesis, especially for guide RNAs used in CRISPR-based therapies, the company has adopted new technologies. According to WuXi TIDES, these include biocatalysis for gRNA synthesis and thin film evaporation (TFE). Biocatalysis offers a more environmentally friendly and potentially more selective route for producing long RNA strands, while TFE is used for concentrating and purifying oligonucleotide solutions without the degradation that can occur with other methods.

Quality assurance is a cornerstone of any pharmaceutical manufacturing operation. WuXi TIDES operates a single quality system across all its sites that has been approved by major regulatory agencies around the world. These agencies include the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), China’s National Medical Products Administration (NMPA), Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), South Korea’s Ministry of Food and Drug Safety (MFDS), and SwissMedic. Having a unified system that passes inspections from such a diverse set of regulators is no small feat. It allows clients to develop their product under one set of quality expectations, reducing the risk of having to revalidate processes for different markets.

Comprehensive Analytical and Drug Product Services

The analytical demands for oligonucleotide therapeutics are among the most rigorous in the pharmaceutical industry. Oligonucleotides are large, charged molecules that can form secondary structures, and their impurities (such as n-1 deletions, depurination, or phosphodiester isomers) can significantly impact safety and efficacy. WuXi TIDES offers a comprehensive analytical platform that includes method development and validation, in-process control (IPC) and release testing, characterization, and stability studies. This platform supports both the active pharmaceutical ingredient (API) and the drug product under one quality system.

Beyond chemistry, formulation development and manufacturing are essential for ensuring that the oligonucleotide reaches its target site in the body. The company provides services for various dosage forms and filling formats. Many oligonucleotides are delivered via injection, but emerging formulations include inhaled, topical, and oral routes. The ability to develop and manufacture these diverse forms within the same organization can accelerate timelines.

Integrated CMC Dossier Preparation and Clinical Supply

Perhaps the most value-added service in a CRDMO platform is the integrated chemistry, manufacturing, and controls (CMC) dossier preparation. Regulatory submissions for oligonucleotide therapeutics require a detailed description of the synthetic process, analytical methods, impurity profiles, stability data, and formulation details. WuXi TIDES offers API process development and manufacturing, formulation development and manufacturing, analytical support, and integrated CMC dossier preparation, as well as clinical supply services. By having all these functions under one roof, the company aims to enable clients to bring their oligonucleotide therapeutics to market faster.

Regulatory agencies have specific expectations for oligonucleotide manufacturing, and the dossier must be comprehensive. For example, the FDA’s guidance on oligonucleotide impurities and the EMA’s requirements for genotoxicity assessment of process-related impurities must be addressed. An integrated platform that has navigated these requirements previously can provide valuable expertise to sponsors, especially smaller biotechnology firms without extensive regulatory experience.

Frequently Asked Questions

Q: What types of oligonucleotides can be synthesized and manufactured on a CRDMO platform?

A: Platforms like the one described by WuXi TIDES cover a wide range, including DNA, antisense oligonucleotides (ASOs), phosphorodiamidate morpholino oligomers (PMOs), microRNA (miRNA), small interfering RNA (siRNA), single guide RNA (sgRNA), and degenerate oligonucleotide pools. They also handle conjugates such as oligonucleotide-peptide, oligonucleotide-drug, oligonucleotide-lipid, oligonucleotide-GalNAc, and dye-labelled oligonucleotides.

Q: How does scaling oligonucleotide synthesis from discovery to commercial manufacturing affect quality?

A: Scaling up from nanomole to mole quantities introduces challenges related to coupling efficiency, impurity accumulation, and solvent handling. An integrated CRDMO platform addresses these by using validated processes, dedicated analytical support at each stage, and a single quality system that meets global regulatory standards from agencies like the FDA and EMA.

Q: What new technologies are used in oligonucleotide manufacturing to improve efficiency?

A: Some platforms have adopted biocatalysis for guide RNA synthesis and thin film evaporation (TFE) for purification and concentration. Biocatalysis offers a greener, more selective method for producing long RNA strands, while TFE helps minimize degradation during processing.

Q: Why is an integrated CMC dossier service important for oligonucleotide therapeutics?

A: Regulatory submissions require a unified description of the synthetic process, analytical methods, formulation, and stability data. Integrated CMC dossier preparation ensures that all components are consistent and that the submission meets the specific requirements of multiple regulatory agencies, accelerating the approval process.